Citable filing context
DHR's research view summarizes recent SEC filing context, starting with management_change from Aug 3, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 3, 2026 | management_change | Julie Sawyer Montgomery was appointed President and CEO, effective October 1, 2026, succeeding Rainer M. Blair. |
| Jul 21, 2026 | earnings | Danaher reported Q2 2026 revenue of $6.3 billion, up 5.5% year-over-year, and increased full-year EPS guidance. |
| Jun 3, 2026 | debt_offering | Danaher issued seven series of senior notes totaling approximately CHF 2.38 billion. |
| Jul 21, 2026 | Guidance: adjusted_diluted_eps | 8.45 to 8.60 |
| Jul 21, 2026 | Guidance: core_revenue_growth | 3.00 to 4.00 |
| Jul 21, 2026 | Guidance: core_revenue_growth | 2.00 to 3.00 |
| Jul 21, 2026 | mda_quarterly | Danaher Corporation’s financial performance for the first half of 2026 was defined by the $9.8 billion acquisition of Masimo Corporation, a developer of patient monitoring technologies, which was integrated into the Diagnostics segment. This acquisition significantly impacted the balance sheet, adding approximately $5.0 billion in goodwill and $4.8 billion in other intangible assets, while necessitating substantial new long-term debt and commercial paper issuances. Operationally, the company reported a 4.5% increase in total sales for the six-month period, with core sales growing 2.0%. Growth was driven by the Life Sciences and Biotechnology segments, though Diagnostics faced headwinds from lower respiratory testing demand. Operating profit margins improved to 20.2% for the six-month period, largely due to the absence of significant 2025 impairment charges, despite being partially offset by $100 million in nonrecurring acquisition-related costs, including inventory fair value adjustments and change-in-control payments associated with Masimo. The company maintains a strong liquidity position with $4.3 billion in cash and equivalents. Management continues to navigate geopolitical risks, including supply chain delays in the Middle East, and ongoing litigation, notably the Hawkins securities class action and various legal disputes involving Masimo and its former CEO, Joe Kiani. |
| Apr 21, 2026 | mda_quarterly | Danaher reported a 3.5% increase in total revenues to $5.95 billion for Q1 2026, with core sales growing 0.5%, primarily boosted by a 3.0% favorable currency impact. Net earnings rose to $1.0 billion, or $1.45 diluted EPS, driven by increased core sales and lower net interest expense, while operating profit margin expanded to 22.6%. The Biotechnology segment led growth with 7.0% core sales increase, fueled by bioprocessing consumables demand from large pharma, particularly in Western Europe and China, despite lower equipment sales. Life Sciences saw 0.5% core sales growth, with consumables and filtration business strength, especially in China, offsetting decreased equipment demand and muted academic spending. Conversely, the Diagnostics segment experienced a 4.0% core sales decline, mainly due to decreased demand for respiratory tests and impacts from China's volume-based procurement and healthcare reimbursement changes, leading to a 140 basis point drop in its operating profit margin. Danaher entered an agreement to acquire Masimo Corporation for approximately $9.9 billion, a specialty diagnostics provider, which will be financed by cash on hand and debt, including a new $5.0 billion 364-day credit facility. Operating cash flow increased to $1.32 billion. Geopolitical instability in the Middle East and uncertainty surrounding new U.S. tariffs pose ongoing risks. |
Source: SEC EDGAR filing text and events; period Aug 3, 2026; filed Aug 3, 2026.
DHR company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.